DelMar Pharmaceuticals (DMPI) Issues Earnings Results

DelMar Pharmaceuticals (NASDAQ:DMPI) released its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, Yahoo Finance reports.

DelMar Pharmaceuticals (NASDAQ:DMPI) traded up $0.03 during mid-day trading on Thursday, reaching $1.36. The company’s stock had a trading volume of 169,800 shares, compared to its average volume of 805,906. The firm has a market cap of $28.73, a P/E ratio of -1.58 and a beta of 1.22. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.20.

Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, January 4th.

ILLEGAL ACTIVITY WARNING: “DelMar Pharmaceuticals (DMPI) Issues Earnings Results” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/delmar-pharmaceuticals-dmpi-issues-earnings-results.html.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply